CJC-1295 + Ipamorelin vs Ipamorelin

CJC-1295 + Ipamorelin

CJC-1295 + Ipamorelin is one preparation holding two separate compounds, a GHRH analogue and a growth hormone secretagogue. Each component has a published literature of its own and a profile of its own on this site. The blend itself has none. No controlled study of the two given together was located. The nearest published work is a 2013 analytical paper describing a method that detects both, among seven peptides, in horse plasma, and a set of recent review articles that list them side by side. Every citation here is attributed to one component or the other.

Ipamorelin

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, that acts as an agonist at the ghrelin receptor, GHS-R1a. It was derived from earlier growth hormone-releasing peptides and is one residue shorter than GHRP-2 and GHRP-6. What set it apart in the original animal pharmacology was selectivity: growth hormone release was not accompanied by the rises in ACTH and cortisol recorded for older compounds in the class. Because ghrelin receptors are also present in the gut, it has been examined in rodent models of gastrointestinal motility, and it has been the subject of a small number of human clinical studies. Human data remain limited, and most of what is known comes from animal work.

How CJC-1295 + Ipamorelin acts

The two components act at different receptors. CJC-1295 is a modified analogue of growth hormone-releasing hormone; a 2006 randomised, placebo-controlled trial in healthy adults reported sustained rises in growth hormone and IGF-1 after a long-acting form of it. Ipamorelin is a pentapeptide that releases growth hormone through the growth hormone secretagogue receptor rather than the GHRH receptor, and its 1998 description in rat pituitary cells, rats and swine reported release without the rise in ACTH and cortisol seen with GHRP-6 and GHRP-2. Nothing published describes what the two do together.

How Ipamorelin acts

Ipamorelin has been reported to bind GHS-R1a on somatotroph cells of the anterior pituitary, where receptor activation raises intracellular calcium and triggers growth hormone secretion. Its reported selectivity concerns other pituitary and adrenal hormones: in the animal studies that first characterised it, ACTH and cortisol did not rise appreciably, unlike with GHRP-6 or GHRP-2. The structural basis for this difference has not been fully explained. The receptor is also found in the gut wall and its nerve supply, which is the rationale for rodent studies of gastrointestinal transit using this compound.

The records side by side

• Type: CJC-1295 + Ipamorelin, Two-peptide blend; Ipamorelin, Growth hormone secretagogue (GHRP)
• Length: CJC-1295 + Ipamorelin, not recorded; Ipamorelin, 5 amino acids
• Molecular weight: CJC-1295 + Ipamorelin, not recorded; Ipamorelin, 711.9 g/mol
• Molecular formula: CJC-1295 + Ipamorelin, not recorded; Ipamorelin, C38H49N9O5

Reading a comparison

A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.